He or she can also look for other signs of illnesses that cause splenomegaly.

The most common finding on physical examination at diagnosis is splenomegaly.

Splenomegaly is frequent toward the end of first week.

Splenomegaly and evidence of mild hypersplenism may affect some patients.

Hypersplenism was noted in four patients, two of whom had palpable splenomegaly.

Ten percent of patients present with splenomegaly and lymphadenopathy.

The natural history is indolent, often marked by anemia and splenomegaly.

Palpable splenomegaly was observed in approximately 30% of patients.

Splenomegaly (enlargement of spleen) may be evident in young fish.

Lymphadenopathy, splenomegaly, and/or hepatomegaly are present in 30-40% of cases.

Both splenomegaly and a tendency towards clot formation feature in this condition.

These patients demonstrate splenomegaly and poor response to low-dose or high-dose chemotherapy.

Approach to the patient with lymphadenopathy and splenomegaly.

Diagnosis can be suspected in case of respiratory infection associated with splenomegaly and/or epistaxis.

Splenic diseases include splenomegaly, where the spleen is enlarged for various reasons.

Splenomegaly may decrease the affected individual's capacity for eating by exerting pressure on the stomach.

An enlarged spleen (splenomegaly) may be found on examination.

Five patients had smooth firm hepatomegaly; none had palpable splenomegaly.

Massive splenomegaly may lead to cytopenias because of hypersplenism and respiratory compromise.

An enlarged spleen (splenomegaly), which can become filled with up to 90% of the body's platelets.

Currently, several such signs of splenomegaly exist, all of whose utility has been debated in medical literature.

The normal human spleen measures about 125 millimeters in length, and splenomegaly is an important clinical sign.

The condition is associated with koilonychia, glossitis, cheilitis, and splenomegaly.

Splenomegaly or hepatosplenomegaly may occasionally be present in association with an overlapping myeloproliferative disorder.

The decision to treat is based on symptomatic cytopenias, massive splenomegaly, or the presence of other complications.